Associations of VEGFR2 rs2305948 polymorphism with long-term prognosis of myocardial infarction

Aim. To evaluate the associations of VEGFR2 rs2305948 polymorphism with the occurrence of cardiovascular events during long-term follow-up in patients with myocardial infarction. Material and methods. The study included 218 patients with acute infarction (MI), mean age 57.7 ± 9.9 years (M ± SD). After clinical examination and preparation, patients urgently underwent coronary angiography followed by percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). All patients underwent determination of the rs2305948 VEGFR2 allelic variant by polymerase chain reaction. The duration of long-term follow-up of these patients was 9 years (from 2015 to 2024). Results. It was determined that during long-term follow-up, patients with rs2305948 VEGFR (C/T and T/T), in contrast to patients with rs2305948 VEGFR (C/C), were more likely to experience cardiovascular death, recurrent acute coronary syndrome (ACS), recurrent revascularization and a combined end point (cardiovascular death, recurrent ACS, coronary stent/bypass thrombosis, acute ischemic cerebrovascular accident, repeated myocardial revascularization). Using multivariate analysis, it was determined that the occurrence of cardiovascular death during long-term follow-up is directly influenced by the Charlton comorbidity index (p < 0.001) and rs2305948 VEGFR2 (C/T and T/T) (p = 0.030). The onset of a combined endpoint is directly determined by the Charlton comorbidity index (p = 0.014) and rs2305948 VEGFR2 (C/T and T/T) (p = 0.034) and vice versa by subsequent outpatient treatment with high doses of statins (p < 0.001). Conclusions. The presence of rs2305948 VEGFR (C/T and T/T) in patients with MI increases the likelihood of cardiovascular death by 2.82 times and the combined endpoint by 2.10 times during long-term follow-up (9 years).